Bioheart Makes Breakthrough In Critical Limb Ischemia Therapy With Stem Cells Obtained From Fat Tissue

Medical News Today | 2009-12-22

Bioheart, Inc. (OTC Bulletin Board: BHRT) offers yet another medical breakthrough with the next-level stem cell treatment for critical limb ischemia patients. The stem cells aid in promoting angiogenesis or the formation of new blood vessels and providing support for the healing of damaged blood vessels.

Bioheart, in collaboration with University Hospital Ostrava in the Czech Republic, has already begun treating patients with critical limb ischemia utilizing ASCs. Bioheart is working to place the TGI systems throughout the Czech Republic for a variety of other indications including acute myocardial infarction and chronic heart ischemia, developing new and special treatment plans for patients with these heart issues.



chatno

PlacidWay

Support